|
Explore a real-world case study on repeat biopsy decision-making during patient monitoring.
|
|
Case Study: Repeat Biopsy or Continued Monitoring?
|
|
A 63-year-old man on active surveillance for Gleason 6 (Grade Group 1) prostate cancer presents with a PSA of 7.2 ng/mL and a family history of prostate cancer. Should he undergo a repeat biopsy?
|
|
|
|
|
In this real-world case study, Dr. Aaron Berger, Chief Medical Officer for Associated Urological Specialists, discusses how the IsoPSA Test informed the clinical evaluation and contributed to the decision to continue active surveillance rather than proceed to biopsy.
|
|
Watch this short video and explore additional case studies to see how the IsoPSA Test can help clinicians enhance risk assessment and support shared decision-making with their patients.
|
|
|
Stay Current with New Clinical Resources
|
|
Subscribe to receive notifications about new CME programs, clinical case studies, and other educational resources as they become available.
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
